10 research outputs found

    Co-Oligomers of Renewable and "Inert" 2-MeTHF and Propylene Oxide for Use in Bio-Based Adhesives

    Get PDF
    Commercial polyether polyols are usually obtained by the ring-opening polymerization of epoxides or tetrahydrofuran. 2-Methyl-tetrahydrofuran (2-MeTHF) could be an alternative bio-based building block for the synthesis of these polyols. Although 2-MeTHF cannot be polymerized, we did achieve the copolymerization of 2-MeTHF with propylene oxide (PO) using Lewis and Brønsted acids as catalysts and water or diols as initiators. The resulting polyether polyols have a molecular weight range, which allows their use as components for adhesives. The molar content of 2-MeTHF in the oligomers can be up to 48%. A 1:1 copolymer of 2-MeTHF and PO is produced when stoichiometric amounts of BF3·OEt2 are used. Here, the monomeric units in the chains alternate, but also cyclic or other nondiol products are formed that are detrimental to its further use in adhesives. Linear dihydroxyl-terminated polyether chains were formed when the heteropolyacid H3PW12O40·24H2O was used as a catalyst and a diol as an initiator. The formation of cyclic products can be drastically reduced when the accumulation of propylene oxide during the reaction is avoided. 1H NMR experiments indicate that the step of 2-MeTHF incorporation is the alkylation of 2-MeTHF by protonated PO. It was shown that the 2-MeTHF/PO copolymer had increased tensile strength compared to polypropylene glycol in a two-component adhesive formulation

    American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

    Get PDF
    10.1002/acr.23834ARTHRITIS CARE & RESEARCH715579-59

    American college of rheumatology provisional criteria for clinically relevant improvement in children and adolescents with childhood-onset systemic Lupus erythematosus

    No full text
    To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRIcSLE). Methods Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRIcSLE and rate a total of 433 unique patient profiles for the presence/absence of CRIcSLE. Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE-CRVs (baseline versus follow-up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]; range 0-1). Results During an international consensus conference, unanimous agreement on a definition of CRIcSLE was achieved; cSLE experts (n = 13) concurred (100%) that the preferred CHILI algorithm considers absolute changes in the cSLE-CRVs. After transformation to a range of 0-100, a CHILI score of >= 54 had outstanding accuracy for identifying CRIcSLE (AUC 0.93, sensitivity 81.1%, and specificity 84.2%). CHILI scores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC >= 0.92, sensitivity >= 93.1%, and specificity >= 73.4%). Conclusion The CHILI is a new, seemingly highly accurate index for measuring CRI in cSLE over time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.715579590CNPQ - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPESP – Fundação de Amparo à Pesquisa Do Estado De São Paulo303422/2015-7; 7/2016-9; 304255/2015-7215/03756-

    IQSEC2-related encephalopathy in males and females: a comparative study including 37 novel patients

    No full text

    Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

    No full text

    Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

    Get PDF
    Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. To identify common PrCa susceptibility alleles, we have previously conducted a genome-wide association study in which 541, 129 SNPs were genotyped in 1,854 PrCa cases with clinically detected disease and 1,894 controls. We have now evaluated promising associations in a second stage, in which we genotyped 43,671 SNPs in 3,650 PrCa cases and 3,940 controls, and a third stage, involving an additional 16,229 cases and 14,821 controls from 21 studies. In addition to previously identified loci, we identified a further seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11, and 22 (P=1.6×10−8 to P=2.7×10−33)
    corecore